This website is intended for healthcare professionals only

Autoimmune Psychosis: Why It Matters

Norio Chihara

Why this topic matters Autoimmune psychosis (AP) is conceptualized as a psychosis-dominant form of autoimmune encephalitis (AE). In contrast to ‘typical’ AE, in which seizures, impaired consciousness and focal deficits rapidly declare a neurological syndrome, patients with AP can initially present to psychiatric services with apparently isolated psychotic or mood symptoms. Overt neurological signs may […]

touchREVIEWS in Neurology. 2026;22(1):Online ahead of journal publication

Neurometabolic Disease

Anti-NMDA Receptor Encephalitis- the clinical criteria of early diagnosis

Published Online: Jul 22nd 2014

Anti-NMDA Receptor Encephalitis- the clinical criteria of early diagnosis.

Tahseen Mozaffar: PROPEL Study Results Investigating the use of AT-GAA for the Treatment of Late-onset Pompe Disease

touchNEUROLOGY caught up with Tahseen Mozaffar (University California, Irvine, CA, USA) to discuss the results from the PROPEL study (NCT03729362) investigating the use of AT-GAA for the treatment of late-onset Pompe disease. Questions: Could you tell us a little about late onset Pompe disease and the unmet needs in its treatment? (0:15) What is AT-GAA […]

Related Videos in Neurometabolic Disease

Antonio Federico, EAN 2018 – Effects of migration on the pathophysiology of neurological conditions

Antonio Federico (EAN Scientific Committee Chair; Professor, Clinical Neurology and Neurometabolic Diseases, University of Siena, Italy) describes the impact increased migration has had on the pathophysiology of neurological conditions and the need to increase awareness of this amongst neurologists. Questions 1. ...

Antonio Federico, EAN 2018 – Involvement of the EAN in rare neurological diseases

Antonio Federico (EAN Scientific Committee Chair; Professor, Clinical Neurology and Neurometabolic Diseases, University of Siena, Italy) discusses the unique challenges that rare neurological diseases bring and how the EAN have a Task Force focused on this important area. Questions 1. Could ...

Günther Deuschl, EAN 2018 – Burden of neurological diseases across Europe (Part 2)

Günther Deuschl (EAN President; Professor of Neurology, Department of Neurology, University Hospital Schleswig-Holstein, Kiel Campus, Germany) kindly took the time to discuss with us the burden of neurological diseases in Europe, including disparities across our continent, and how the ...

Günther Deuschl, EAN 2018 – Burden of neurological diseases across Europe (Part 1)

Thapanee Somboon, AAN 2018 – Neurology and sleep-disordered breathing/sleep apnea

Thapanee Somboon (Cleveland Clinic, OH) talks us through the key findings of her two presentations, which focused on the prevalence of high risk obstructive sleep apnea and insomnia in neurological populations (abstract available here) and the performance of sleep apnea ...

New Antisense Therapy in Development for Pompe Disease

In this exclusive interview during WORLDSymposium 2015, Nicholas Clayton, MSc, staff scientist at Genzyme Corporation discusses the exciting new data he and his colleagues presented on antisense therapy that is in development to treat patients with Pompe disease.

Niemann-Pick Disease Type C

Dr. Marc Patterson a pediatric neurologist at Mayo Clinic discusses Niemann-Pick disease type C.

Pompe Disease

Priya Kishnani, MD, professor of Pediatrics at Duke University School of Medicine and practicing geneticist at Duke Children's Hospital discusses our current understanding of the pathophysiology and management of Pompe disease.

New Treatment Option for Niemann-Pick Type B Disease

Beth Thurberg, MD, PhD, vice president of Pathology at Genzyme Corporation discusses the results of clinical trial looking at clearance of sphingomyelin with recombinant human acid sphingomyelinase administration in patients with Niemann-Pick Type B disease. ...

New Treatment Option for Niemann-Pick Type B

Looking at clearance of sphingomyelin with recombinant human acid sphingomyelinase administration in patients with Niemann-Pick Type B disease. ...

New Antisense Therapy in Development for Pompe Disease

Niemann-Pick type C disease

For patients with Niemann-Pick type C (NPC) disease, the test will make it possible to begin treatment earlier, when it is more likely to improve quality of life. The fatal genetic disorder frequently takes years to diagnose, and earlier detection ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Keep track of your clinical interests and newsletter subscriptions.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

Register now for FREE access

Already registered? Login below.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Learning Activities

Congress Highlights

Journals

Specialities

Autoimmune Psychosis: Why It Matters

Learning Activities

Congress Highlights

Journals

Specialities

Autoimmune Psychosis: Why It Matters

Anti-NMDA Receptor Encephalitis- the clinical criteria of early diagnosis

Register now for
FREE access

Tahseen Mozaffar: PROPEL Study Results Investigating the use of AT-GAA for the Treatment of Late-onset Pompe Disease

Antonio Federico, EAN 2018 – Effects of migration on the pathophysiology of neurological conditions

Antonio Federico, EAN 2018 – Involvement of the EAN in rare neurological diseases

Günther Deuschl, EAN 2018 – Burden of neurological diseases across Europe (Part 2)

Günther Deuschl, EAN 2018 – Burden of neurological diseases across Europe (Part 1)

Thapanee Somboon, AAN 2018 – Neurology and sleep-disordered breathing/sleep apnea

New Antisense Therapy in Development for Pompe Disease

Niemann-Pick Disease Type C

Pompe Disease

New Treatment Option for Niemann-Pick Type B Disease

New Treatment Option for Niemann-Pick Type B

New Antisense Therapy in Development for Pompe Disease

Niemann-Pick type C disease

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Learning Activities

Congress Highlights

Journals

Specialities

Congress Highlights

Trending Topic

Connect With Us:

Anti-NMDA Receptor Encephalitis- the clinical criteria of early diagnosis

Register now forFREE access

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

Register now for FREE access

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Register now for
FREE access